Prostatic Neoplasms, Castration-Resistant

"Prostatic Neoplasms, Castration-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

Descriptor ID	D064129
MeSH Number(s)	C04.588.945.440.770.500 C12.294.260.750.500 C12.294.565.625.500 C12.758.409.750.500
Concept/Terms	Prostatic Neoplasms, Castration-Resistant Prostatic Neoplasms, Castration-Resistant Castration-Resistant Prostatic Neoplasm Neoplasm, Castration-Resistant Prostatic Neoplasms, Castration-Resistant Prostatic Prostatic Neoplasm, Castration-Resistant Prostatic Neoplasms, Castration Resistant Androgen-Insensitive Prostatic Neoplasms Androgen Insensitive Prostatic Neoplasms Androgen-Resistant Prostatic Neoplasms Androgen Resistant Prostatic Neoplasms Prostatic Neoplasms, Hormone Refractory Hormone Refractory Prostatic Neoplasms Prostatic Neoplasms, Androgen-Independent Androgen-Independent Prostatic Neoplasm Neoplasm, Androgen-Independent Prostatic Neoplasms, Androgen-Independent Prostatic Prostatic Neoplasm, Androgen-Independent Prostatic Neoplasms, Androgen Independent Prostatic Neoplasms, Androgen-Insensitive Androgen-Insensitive Prostatic Neoplasm Neoplasm, Androgen-Insensitive Prostatic Neoplasms, Androgen-Insensitive Prostatic Prostatic Neoplasm, Androgen-Insensitive Prostatic Neoplasms, Androgen Insensitive Prostatic Neoplasms, Androgen-Resistant Androgen-Resistant Prostatic Neoplasm Neoplasm, Androgen-Resistant Prostatic Neoplasms, Androgen-Resistant Prostatic Prostatic Neoplasm, Androgen-Resistant Prostatic Neoplasms, Androgen Resistant Androgen-Independent Prostatic Neoplasms Androgen Independent Prostatic Neoplasms Castration-Resistant Prostatic Neoplasms Castration Resistant Prostatic Neoplasms Prostatic Cancer, Castration-Resistant Prostatic Cancer, Castration-Resistant Cancer, Castration-Resistant Prostatic Cancers, Castration-Resistant Prostatic Castration-Resistant Prostatic Cancers Prostatic Cancer, Castration Resistant Prostatic Cancers, Castration-Resistant Androgen-Insensitive Prostatic Cancer Androgen Insensitive Prostatic Cancer Androgen-Resistant Prostatic Cancer Androgen Resistant Prostatic Cancer Prostatic Cancer, Hormone Refractory Hormone Refractory Prostatic Cancer Prostatic Cancer, Androgen-Independent Androgen-Independent Prostatic Cancers Cancer, Androgen-Independent Prostatic Cancers, Androgen-Independent Prostatic Prostatic Cancer, Androgen Independent Prostatic Cancers, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Androgen-Insensitive Prostatic Cancers Cancer, Androgen-Insensitive Prostatic Cancers, Androgen-Insensitive Prostatic Prostatic Cancer, Androgen Insensitive Prostatic Cancers, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Androgen-Resistant Prostatic Cancers Cancer, Androgen-Resistant Prostatic Cancers, Androgen-Resistant Prostatic Prostatic Cancer, Androgen Resistant Prostatic Cancers, Androgen-Resistant Androgen-Independent Prostatic Cancer Androgen Independent Prostatic Cancer Castration-Resistant Prostatic Cancer Castration Resistant Prostatic Cancer

Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms, Castration-Resistant".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Genital Neoplasms, Male [C04.588.945.440]
Prostatic Neoplasms [C04.588.945.440.770]
Prostatic Neoplasms, Castration-Resistant [C04.588.945.440.770.500]
Male Urogenital Diseases [C12]
Genital Diseases, Male [C12.294]
Genital Neoplasms, Male [C12.294.260]
Prostatic Neoplasms [C12.294.260.750]
Prostatic Neoplasms, Castration-Resistant [C12.294.260.750.500]
Prostatic Diseases [C12.294.565]
Prostatic Neoplasms [C12.294.565.625]
Prostatic Neoplasms, Castration-Resistant [C12.294.565.625.500]
Urogenital Neoplasms [C12.758]
Genital Neoplasms, Male [C12.758.409]
Prostatic Neoplasms [C12.758.409.750]
Prostatic Neoplasms, Castration-Resistant [C12.758.409.750.500]

Below are MeSH descriptors whose meaning is related to "Prostatic Neoplasms, Castration-Resistant".

Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms, Castration-Resistant".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prostatic Neoplasms, Castration-Resistant" by people in this website by year, and whether "Prostatic Neoplasms, Castration-Resistant" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2016 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2015	1	0	1
2016	1	1	2
2018	1	1	2
2021	1	0	1
2022	1	0	1
2023	1	0	1
2025	1	0	1

Below are the most recent publications written about "Prostatic Neoplasms, Castration-Resistant" by people in Profiles.

Candelieri-Surette D, Lee J, Lynch JA, Chang NN, Nelson TJ, Teerlink CC, Pimentel C, Schoen MW, Berlowitz D. Epidemiology of Metastatic Castration-Resistant Prostate Cancer in Veterans Nationwide. J Natl Compr Canc Netw. 2025 Jul 14; 23(8):307-313.

View in: PubMed
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, Al-Eryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Sch?rer S, Swarbrick A, Sykes DB, Patnaik A. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer. Clin Cancer Res. 2023 05 15; 29(10):1952-1968.

View in: PubMed
Nuvola G, Santoni M, Rizzo M, Rosellini M, Mollica V, Rizzo A, Marchetti A, Battelli N, Massari F. Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer. Expert Rev Anticancer Ther. 2023 06; 23(6):593-600.

View in: PubMed
Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, Hadaschik BA, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy DG, Oprea-Lager DE, O'Sullivan JM, Oyen WJG, Rouvi?re O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, Bjartell A. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022 10; 5(5):530-536.

View in: PubMed
Santoni M, Massari F, Rizzo A, Mollica V, Cimadamore A, Montironi R, Battelli N. Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori. 2023 Apr; 109(2):157-163.

View in: PubMed
Rizzo A, Mollica V, Merler S, Morelli F, Sorgentoni G, Oderda M, Santoni M, Massari F. Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. Expert Opin Drug Metab Toxicol. 2022 Mar; 18(3):235-240.

View in: PubMed
Rizzo A, Oderda M, Mollica V, Merler S, Morelli F, Fragomeno B, Taveri E, Sorgentoni G, Santoni M, Massari F. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anticancer Drugs. 2022 01 01; 33(1):e43-e51.

View in: PubMed
Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, Cheng L, Massari F. Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Rev Anticancer Ther. 2022 Feb; 22(2):191-202.

View in: PubMed
Mollica V, Marchetti A, Rosellini M, Nuvola G, Rizzo A, Santoni M, Cimadamore A, Montironi R, Massari F. An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. Int J Mol Sci. 2021 Dec 16; 22(24).

View in: PubMed
Rizzo A, Merler S, Sorgentoni G, Oderda M, Mollica V, Gadaleta-Caldarola G, Santoni M, Massari F. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. Expert Opin Drug Metab Toxicol. 2021 Oct; 17(10):1237-1243.

View in: PubMed

People

Explore

Similar Concepts

Top Journals